WNT5A and prostate carcinoma: WNT5A was shown to promote prostate cancer cell dormancy in bone.5 Thus, the researchers hypothesized that sFRP1 may reactivate dormant melanoma cells and resume proliferation by inhibiting WNT5A signaling.